SCHEMBL4416535

SCHEMBL4416535

[CH2]c1ccc(OCCN2CCCCC2)c(F)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.60
ESR1 P03372 1/20 0.55
ESR2 Q92731 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.54
KDM4E B2RXH2 2/20 0.50
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
KMT2A Q03164 1/20 0.50
TSHR P16473 1/20 0.49
KDR P35968 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
HTR2C P28335 2/20 0.45
HRH1 P35367 2/20 0.45
DRD2 P14416 1/20 0.45
DRD1 P21728 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19581760 0.98 LTA4H (0.61) LTA4HESR1ESR2SMN1; SMN2KDM4E
SCHEMBL19581649 0.91 KDM4E (0.57) LTA4HESR1ESR2SMN1; SMN2KDM4E
SCHEMBL19581801 0.87 KDM4E (0.51) LTA4HESR1ESR2SMN1; SMN2KDM4E
SCHEMBL18010724 0.82 SMN1; SMN2 (0.74) LTA4HESR1ESR2SMN1; SMN2KDM4E
SCHEMBL226018 0.82 LTA4H (0.60) LTA4HESR1ESR2SMN1; SMN2KDM4E
SCHEMBL227430 0.82 LTA4H (0.60) LTA4HESR1ESR2SMN1; SMN2KDM4E
SCHEMBL3442370 0.82 LTA4H (0.60) LTA4HESR1ESR2SMN1; SMN2KDM4E
SCHEMBL19582199 0.81 TSHR (0.61) LTA4HSMN1; SMN2KDM4EALDH1A1CYP1A2
SCHEMBL2324209 0.81 LTA4H (0.61) LTA4HESR1ESR2SMN1; SMN2KDM4E
SCHEMBL2322184 0.81 LTA4H (0.61) LTA4HESR1ESR2SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325930-A1 SELECTIVE ESTROGEN RECEPTOR MODULATOR RADIUS HEALTH, INC. 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325930-A1 SELECTIVE ESTROGEN RECEPTOR MODULATOR ESR1, GPER1, ESR2 LTA4H 3180/4885ESR1 1/4885ESR2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.